Loading…
Chinese biotech developing monoclonal antibodies and antibody-drug conjugates (ADCs) for cancer and other diseases.
Chinese biotech developing monoclonal antibodies and antibody-drug conjugates (ADCs) for cancer and other diseases.
In one line: A Chinese ADC-focused biotech, akin to a smaller Seagen.
Moat: narrow (IP / patents). Patent-protected antibody/ADC pipeline built on in-house biologics R&D.
Headquarters: Shanghai, China · Employees: 1,325
Size Mabwell (Shanghai) Bioscience (688062.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $1.44B, the 1690th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥22.08 on 6 Nov 2026.
Performance Over six months the shares fell 38.2%, against -16.7% for the median peer and -16.4% for the China market (cap-weighted) — 4th lowest of 21 in its peer set.
Growth Revenue grew 14.9% over the last twelve months (peer median +9.2%); the operating margin is -128.8% (peer median -2.1%).
Valuation It trades at 15.5× enterprise value to sales against a peer median of 8.9× (7th most expensive of 18).
Capital Return on invested capital runs 32.8 points below its cost of capital (9.4% WACC).
Next results Next results expected around 7 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥718M | CN¥661M | CN¥198M | CN¥127M | CN¥27.7M |
| Revenue growth | — | +233% | +57% | +357% | — |
| Gross profit | CN¥594M | CN¥387M | CN¥39.6M | CN¥15.8M | -CN¥68.2M |
| EBITDA | n/a | -CN¥672M | -CN¥885M | -CN¥979M | -CN¥907M |
| Net income | -CN¥1.05B | -CN¥969M | -CN¥1.04B | -CN¥1.05B | -CN¥955M |
| Free cash flow | -CN¥1.04B | -CN¥447M | -CN¥1.28B | -CN¥1.28B | -CN¥1.26B |
| Capital expenditure | CN¥107M | CN¥158M | CN¥330M | CN¥500M | CN¥545M |
| Total debt | CN¥3.69B | CN¥2.97B | CN¥2.22B | CN¥1.29B | CN¥774M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Mabwell (Shanghai) Bioscience 688062.SS | $1.44B | -38% | +15% | -129% | 15.5× | n/a |
| RemeGen 688331.SS | $6.90B | -26% | +272% | 61% | 4.9× | 2.8% |
| Innovent Biologics 1801.HK | $19.2B | -5% | +43% | 17% | 7.4× | 11.7% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 688062.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -9.2% | -3.6% | 7th lowest of 21 |
| 6-month return | -38.2% | -16.7% | 4th lowest of 21 |
| Distance from 52-week high | -54.5% | -40.1% | 7th lowest of 21 |
| Revenue growth (TTM) | +14.9% | +9.2% | 8th highest of 18 |
| Operating margin | -128.8% | -2.1% | 6th lowest of 18 |
| EV / Sales | 15.5× | 8.9× | 7th most expensive of 18 |
| ROIC minus cost of capital | -32.8 pp | -6.2 pp | 6th lowest of 17 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Mabwell (Shanghai) Bioscience 688062.SS | China | $1.44B | -38% | +15% | -129% | 15.5× | n/a | n/a |
| Ocular Therapeutix OCUL | United States | $1.45B | -32% | -8% | -603% | 17.9× | n/a | n/a |
| Nippon Shinyaku 4516.T | Japan | $1.43B | -30% | +12% | 19% | 0.9× | -17.5% | +7.0% |
| Structure Therapeutics, Inc. Sponsored ADR GPCR | United States | $1.45B | -48% | n/a | n/a | n/a | n/a | n/a |
| Mezzion Pharma 140410.KS | South Korea | $1.42B | -29% | +7% | -223% | 226.6× | n/a | n/a |
| Pacira Biosciences PCRX | United States | $1.45B | +57% | +6% | 4% | 2.2× | 14.9% | +11.1% |
| Marksans Pharma MARKSANS.NS | India | $1.45B | +50% | +24% | 20% | 3.9× | 31.6% | +16.6% |
| Damora Therapeutics DMRA | United States | $1.46B | -2% | n/a | n/a | n/a | n/a | n/a |
| Staidson (Beijing) Biopharmaceuticals 300204.SZ | China | $1.41B | -36% | -24% | -51% | 44.5× | n/a | n/a |
| Anupam Rasayan India ANURAS.NS | India | $1.40B | -15% | +52% | 16% | 5.2× | n/a | n/a |
| Shenzhen Chipscreen Biosciences 688321.SS | China | $1.40B | -33% | +27% | 12% | 8.9× | n/a | n/a |
| Zhejiang Hisoar Pharmaceutical 002099.SZ | China | $1.39B | -9% | +9% | -13% | 4.9× | n/a | n/a |
| ABL Bio 298380.KS | South Korea | $1.49B | -73% | -64% | -251% | 55.7× | n/a | n/a |
| Ascentage Pharma Group International 6855.HK | Hong Kong | $1.39B | -33% | +70% | -220% | 15.5× | n/a | n/a |
| Zhejiang Jingxin Pharmaceutical 002020.SZ | China | $1.49B | -17% | +1% | 19% | 2.3× | -8.5% | +4.6% |
| Innoviva INVA | United States | $1.38B | -17% | +18% | 36% | 2.4× | -15.4% | +3.9% |
| Ultragenyx Pharmaceutical RARE | United States | $1.52B | +22% | +16% | -64% | 3.3× | n/a | n/a |
| LB Pharmaceuticals LBRX | United States | $1.36B | +31% | n/a | n/a | n/a | n/a | n/a |
| Guangdong Taienkang Pharmaceutical 301263.SZ | China | $1.53B | -17% | +2% | -2% | 15.1× | n/a | n/a |
| Shanghai OPM Biosciences 688293.SS | China | $1.35B | +26% | +133% | 11% | 9.8× | 26.1% | +23.1% |
| Nanobiotix NANO.PA | France | $1.54B | -42% | -77% | -392% | 164.1× | n/a | n/a |